Activators & Inhibitors

Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.

Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.

BMN673 is a potent and selective PARP1/2 inhibitor with Ki of 1.2 and 0.9 nM, respectively.

BMN673 is a potent and selective PARP1/2 inhibitor with Ki of 1.2 and 0.9 nM, respectively.

BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM(PARP1). It does not inhibit PARG and is highly sensitive to PTEN mutation. BMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673.

BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM(PARP1). It does not inhibit PARG and is highly sensitive to PTEN mutation. BMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673.

A synthetic peptide that irreversibly inhibits activity of caspase family proteases and blocks apoptosis. The inhibitor is designed as a methyl ester to facilitate cell permeability. Can be used for both in vitro and in vivo studies--see note for using this product in vitro.

A synthetic peptide that irreversibly inhibits activity of caspase family proteases and blocks apoptosis. The inhibitor is designed as a methyl ester to facilitate cell permeability. Can be used for both in vitro and in vivo studies--see note for using this product in vitro.

A synthetic peptide that irreversibly inhibits activity of caspase family proteases and blocks apoptosis. The inhibitor is designed as a methyl ester to facilitate cell permeability. Can be used for both in vitro and in vivo studies--see note for using this product in vitro.